CRF Health announces reporting enhancements to its TrialManager platform for real-time analysis and management of data collected in clinical trials.
Plymouth Meeting, PA â May 31 2016: CRF Health, the leading global provider of eCOA solutions for the life sciences industry, today announced reporting enhancements to TrialManager, its real-time portal for the analysis and management of data collected in clinical trials. The updates bring easy-to-use, role-based visual access to key trial information, further supporting a powerful toolset for the analysis of patient and site data. TrialManager 6.0 delivers next generation reporting and data analysis tools for clinical trials. The totally redesigned data visualization tools provide users with powerful interactive dashboards which facilitate the analysis of data in multiple dimensions, driving data discovery and user insight. A built-in library of best practice reports is available to suit the needs of different trials, and customized reports can be designed to address unique study needs. “TrialManager’s enhanced reporting and data visualization capabilities make it possible for study teams to gain new insight into patient behavior. In a recent study of diabetes, the solution was used to analyze data to identify patterns in meal reporting, glucose measurements and hypoglycemic events”, comments Rauha Tulkki-Wilke, Vice President, Product & Service Management at CRF Health. “For this protocol, the solution provided us with understanding of how timely patients report meals, enabling us to optimize retrospective data entry capabilities to balance accuracy and data volume. Ultimately, this type of insight ensures the capture of higher quality data and drives more detailed analysis.” TrialManager delivers real-time monitoring and management of eCOA data via an online portal which makes it easy to instantly explore and review data collected using any of CRF Health’s TrialMax modalities. Users can simply track compliance and react in real-time to medical alerts based on patient insight, while a customizable dashboard displays the most meaningful trial data to gain a better perspective of sites and patients. For further information on CRF Health's TrialManager solution, please visit www.crfhealth.com. About CRF Health CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 800 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention. CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.